Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis.
about
Bosutinib, a Lyn/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Bosutinib, a Lyn/Btk inhibitin ...... dvanced systemic mastocytosis.
@en
Bosutinib, a Lyn/Btk inhibitin ...... dvanced systemic mastocytosis.
@nl
type
label
Bosutinib, a Lyn/Btk inhibitin ...... dvanced systemic mastocytosis.
@en
Bosutinib, a Lyn/Btk inhibitin ...... dvanced systemic mastocytosis.
@nl
prefLabel
Bosutinib, a Lyn/Btk inhibitin ...... dvanced systemic mastocytosis.
@en
Bosutinib, a Lyn/Btk inhibitin ...... dvanced systemic mastocytosis.
@nl
P2093
P2860
P356
P1476
Bosutinib, a Lyn/Btk inhibitin ...... dvanced systemic mastocytosis.
@en
P2093
Celalettin Ustun
Elizabeth L Courville
Lawrence Afrin
Linda Baughn
Nicole Randall
P2860
P356
10.1002/AJH.23942
P577
2015-03-02T00:00:00Z